- Developed a 'Niclosamide-based multi-treatment drug' that can
simultaneously treat mosquito-borne viral infections such as four
serotypes of dengue virus, Zika, Chikungunya, and Yellow
Fever.
- Accelerating preparations for dengue fever basket clinical
trial scheduled to be conducted in Brazil.
SEOUL,
South Korea, June 25,
2024 /PRNewswire/ -- Hyundai Bioscience (CEO Oh
Sang-gi), which is preparing for a dengue fever basket clinical
trial in Brazil, announced on the
24th that it has successfully developed a 'multi-treatment drug for
mosquito-borne viral infections, including dengue fever,' using
niclosamide as the main ingredient. This treatment, which contains
niclosamide as the main active pharmaceutical ingredient, can
maintain a blood niclosamide concentration (IC50) to inhibit the
proliferation of viruses such as the four serotypes of dengue
virus, Zika, Chikungunya, and Yellow Fever, by 50%.
![Hyundai Bioscience Logo (PRNewsfoto/Hyundai Bioscience) Hyundai Bioscience Logo (PRNewsfoto/Hyundai Bioscience)](https://mma.prnewswire.com/media/2246382/Logo_Logo.jpg)
To effectively treat dengue fever, the antiviral must be
administered early, before the viral load increases significantly.
For early administration, the treatment must be effective not only
against dengue fever but also against other mosquito-borne viral
diseases with similar symptoms, such as Zika, Chikungunya, and
Yellow Fever. Leveraging its patented technology, Hyundai
Bioscience has enhanced the bioavailability of niclosamide,
enabling it to treat arbovirus infections caused by Zika,
Chikungunya, and Yellow Fever viruses in addition to dengue fever.
Recently, the company has succeeded in developing a
"niclosamide-based multi-treatment for mosquito-borne viral
infections" that can maintain an IC50 in the blood to inhibit the
replication of these viruses.
Currently, there is no treatment for dengue fever. The dengue
virus has four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), each
with different IC50 values. The IC50 values for Zika, Chikungunya,
and Yellow Fever viruses, which are also mosquito-borne, vary as
well. Hyundai Bioscience's multi-treatment drug candidate is the
world's first to maintain niclosamide's blood concentration above
the IC50 value of all four serotypes of dengue virus as well as
Zika, Chikungunya, and Yellow Fever viruses.
Hyundai Bioscience has formulated the multi-treatment antiviral
into a tablet form to facilitate mass production and to make it
convenient for transportation and storage.
Hyundai Bioscience has decided to conduct the dengue fever
basket clinical trial in Brazil,
the country most affected by dengue fever. Hyundai Bioscience
USA will soon select a Contract
Research Organization (CRO).
The dengue fever clinical trial, to be conducted by Hyundai
Bioscience USA in Brazil, will use a basket clinical trial
approach, differing from traditional clinical trial methods. This
involves early administration of the multi-target antiviral to
patients infected with mosquito-borne viruses, including the four
serotypes of dengue virus, Zika, and Chikungunya, followed by
evaluating the clinical efficacy in patients with confirmed dengue
virus.
Kim Kyung-il, CEO of Hyundai
Bioscience USA, stated, "With the
development of a multi-treatment drug candidate capable of
simultaneously treating various mosquito-borne viral infections
such as dengue fever, we plan to conduct the basket clinical trial
in Brazil as soon as possible.
Through expedited regulatory processes in Brazil, we aim to supply the treatment at an
affordable price to patients suffering from dengue fever
worldwide."
About Hyundai Bioscience
Hyundai Bioscience is a biotechnology company that develops
new drugs based on its novel drug delivery system technologies to
deliver active ingredients safely and efficiently to targeted areas
of the human body. Founded in 2000, Hyundai Bioscience focuses on
repurposing or expanding indications of existing drugs using its
proprietary organic-inorganic hybrid technologies. Hyundai
Bioscience is a public company listed on KOSDAQ (symbol: 048410) in
South Korea.
For more information, please contact Ms. Joobin Jung, Global PR Manager
(joobin@hyundaibio.com).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hyundai-bioscience-succeeds-in-developing-multi-treatment-for-mosquito-borne-viral-infections-including-dengue-fever-302182515.html
SOURCE Hyundai Bioscience